Studies on the development of novel pharmacotherapy for schizophrenia that regulates the glutamate receptors

为了进一步了解精神分裂症的病理生理学和新药物治疗的发展，特别是对目前使用的抗精神病药物耐药的NMDA型谷氨酸受体拮抗剂引起的精神分裂症样症状，我们研究并增加了关于NMDA型谷氨酸受体生理功能所需的组织和细胞外D-丝氨酸含量调节的分子和细胞机制的新发现。我们还推进了阐明机制所需的转基因动物的过程。

To obtain further insight into the pathophysiology of and the development of a novel pharmacotherapy for schizophrenia with a special attention on the schizophrenia-like symptoms induced by NMDA type glutamate receptor antagonists that are resistant to the currently used antipsychotics, we have studied and added new findings on the molecular and cellular mechanisms underlying regulation of tissue and extracellular contents of D-serine that is required for the physiological functions of the NMDA receptor. We also advanced the processes of the genetically modified animals needed to clarify the mechanisms.